Small Molecules News and Research

RSS

AusBiotech 2010 set to demystify the impact of US Healthcare Reforms on Australian biotech

Australian biotechnology and pharmaceutical companies are seeking to understand the implications of the US Healthcare Reform Bill, says Australia’s biotechnology industry organisation, AusBiotech. In order to remain compliant and globally competitive, biotechs need to identify and work within a gamut of new requirements, complications and hurdles imposed by this new regulatory environment.

13 Oct 2010

Scientists engineer bacterial cell wall with small molecules to combat diseases

A team of Yale University scientists has engineered the cell wall of the Staphylococcus aureus bacteria, tricking it into incorporating foreign small molecules and embedding them within the cell wall.

8 Oct 2010

Role of TGF-ß in cancer diseases

During this year's BIOTECHNICA exhibition, the international biotech news magazine „GEN - Genetic Engineering & Biotechnology News yesterday on 5 October 2010, held an information event with subsequent panel discussion featuring the topic TGF-ß an important target in cancer diseases.

7 Oct 2010

Nuevolution enters lead discovery collaboration for epigenetic disorders

Nuevolution A/S today announced that it has entered into a lead discovery collaboration focused on epigenetic disorders.A consortium between Nuevolution, EpiTherapeutics, ExpreS2ion Biotechnologies and the research group of Professor Kristian Helin (Biotech Research & Innovation Centre, University of Copenhagen) has been established with the objective of identifying and developing novel small molecule drugs against epigenetic factors.

6 Oct 2010

Lixte, NCI collaborate for clinical evaluation of LB-100 compound

Lixte Biotechnology Holdings announced today that the National Cancer Institute Experimental Therapeutics (NExT) Program Senior Advisory Committee (SAC), Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI), National Institutes of Health (NIH), signed a NExT Material Transfer Agreement formalizing a collaboration with Lixte Biotechnology Holdings, Inc. for clinical evaluation of LB-100, one of Lixte's lead anti-cancer compounds.

6 Oct 2010

CPF honors three critical areas of leadership for Pulmonary Fibrosis community

The Coalition for Pulmonary Fibrosis (CPF) has announced its annual awards honoring three critical areas of leadership that impact the work of the Pulmonary Fibrosis (PF) community.

5 Oct 2010

NIH awards contract to develop nanotechnology tools for atherosclerosis treatment

Georgia Tech and Emory University have received a five-year $14.6 million contract from the National Institutes of Health (NIH) to continue the development of nanotechnology and biomolecular engineering tools and methodologies for detecting and treating atherosclerosis.

5 Oct 2010

Washington University receives award to develop diagnostic tools for heart, lung diseases using nanotechnology

An $18 million research program headed by Washington University School of Medicine in St. Louis will research therapies and diagnostic tools for heart and lung diseases that use nanotechnology.

30 Sep 2010

Researchers receive NIH award to investigate regenerative potential of retinal cells

Zhang and co-principal investigators Sheng Ding, PhD, from The Scripps Research Institute, and Thomas Reh, PhD from the University of Washington, received the highest possible scores for their proposal to investigate the regenerative potential of retinal cells. Their long-term goal is to restore visual function lost through diseases such as macular degeneration and retinitis pigmentosa.

30 Sep 2010

NEUROKIN accentuates its leadership in the treatment of acute neurological diseases

Bbiotechnology company NEUROKIN, dedicated to the development of neuroprotective drugs to treat acute neurological diseases, announces today that the European Patent Office (EPO) has granted patent EP 1998778 protecting the use of NK-102, its most advanced drug candidate. This first European award constitutes an important milestone for NEUROKIN. An application for registration is under way in Brazil, Canada, China, USA and Japan.

29 Sep 2010

Pulmokine receives NIH SBIR grants to develop novel treatments for PAH

YM BioSciences Inc., today reported that Pulmokine Inc. (Slingerlands, New York), a licensee of several small molecule compounds from YM, has been awarded two National Institutes of Health (NIH) Small Business Innovation Research (SBIR) grants. The grants, totaling more than US$650,000, are Phase I awards to develop novel treatments for Pulmonary Arterial Hypertension (PAH).

29 Sep 2010

KINAXO, Daiichi Sankyo enter long-term partnership in cancer research

KINAXO Biotechnologies GmbH and Daiichi Sankyo Company Limited entered a long-term partnership in cancer research. Under the agreement, Daiichi Sankyo will employ KINAXO's technology platform to support the development of Daiichi Sankyo's targeted cancer drugs.

29 Sep 2010

BioSeek signs two-year agreement with Cellzome

Asterand plc, a leading provider of human tissue and human tissue-based research services to pharmaceutical and biotechnology companies engaged in drug discovery research, today announced that its subsidiary BioSeek, LLC, a pioneer in the application of predictive human biology to drug discovery, has signed a two-year agreement with Cellzome.

24 Sep 2010

Weight-based taribavirin reduces anemia, increases sustained virologic response

Researchers at Cedars-Sinai Medical Center and 50 other centers found that weight-based dosing of taribavirin reduces rates of anemia while increasing sustained virologic response (SVR) in patients with chronic hepatitis C (HCV). Full details of this study are available in the October issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).

23 Sep 2010

Crestor suppressed human cancer cells transplanted to mice

A drug commonly prescribed for people with high cholesterol may also be effective in treating prostate cancer, according to new research by Dr. Xiao-Yan Wen at St. Michael's Hospital.

20 Sep 2010

Researchers identify role of bile acid in lifespan extension

The human quest for longer life may be one step closer, thanks to research from Concordia University. Published in the journal Aging, a new study is the first to identify the role of a bile acid, called lithocholic acid (LCA), in extending the lifespan of normally aging yeast. The findings may have significant implications for human longevity and health, as yeast share some common elements with people.

16 Sep 2010

Wintherix announces WX04554 molecule can cause bone healing

Wintherix, LLC, a privately held biotechnology company focusing on bone healing and regenerative medicine, today announced that WX04554, a potent small molecule activator of the Wnt pathway, has been designated as a lead drug for clinical development in bone healing and repair indications.

15 Sep 2010

microRNA 451 enhances treatment response in stomach cancer patients: Research

"The high presence of microRNA 451 enhances the response to treatment with chemo-radiotherapy and increases the survival of patients with stomach cancer", explained Dr. Jesús García-Foncillas, chief researcher of the Pharmacogenomics Laboratory at the Applied Medical Research Centre (CIMA) and Director of Oncology at the University Hospital of Navarra. This was one of the results presented at the IV Congress of the Spanish Society for Pharmacogenetics and Pharmacogenomic, recently held at CIMA.

15 Sep 2010

Researchers identify body's control switch system to eliminate damaged cells

St. Jude Children's Research Hospital scientists discovered a new mechanism cells use to maximize production of a key protein following DNA damage and demonstrated the potential of small molecules to regulate the process and protect healthy tissue.

14 Sep 2010

Researchers synthesize new compounds to reduce A-beta 42 peptide in Alzheimer's disease

A team of scientists, led by University of California, San Diego School of Medicine researchers, has synthesized hundreds of new compounds with the potential of reducing the production of the A-beta 42 peptide, a primary component of Alzheimer's disease (AD).

9 Sep 2010